Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.81 [0.54, 1.21] | | < 1 | | 73% | 2 studies (2/-) | 84.6 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 0.78 [0.60, 1.03] | | < 1 | | 0% | 2 studies (2/-) | 96.2 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 1.77 [0.43, 7.29] | | > 1 | | 87% | 2 studies (2/-) | 78.6 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.57 [0.30, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 96.0 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) | 0.58 [0.27, 1.27] | | < 1 | | 76% | 2 studies (2/-) | 91.2 % | some concern | not evaluable | moderate | non important | - |
AE leading to death (grade 5) | 1.34 [0.37, 4.91] | | < 1 | | 55% | 2 studies (2/-) | 32.9 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (any grade) | 0.71 [0.48, 1.05] | | < 1 | | 0% | 2 studies (2/-) | 95.6 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 1.10 [0.64, 1.89] | | < 1 | | 0% | 1 study (1/-) | 35.9 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.34 [0.90, 1.99] | | < 1 | | 0% | 2 studies (2/-) | 7.4 % | some concern | not evaluable | moderate | non important | - |
STRAE (any grade) | 0.61 [0.40, 0.94] | | < 1 | | 0% | 2 studies (2/-) | 98.7 % | some concern | not evaluable | moderate | non important | - |
STRAE (grade 3-4) | 0.48 [0.28, 0.84] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.24 [0.17, 0.32] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.24 [0.10, 0.58] | | < 1 | | 68% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 0.69 [0.13, 3.52] | | < 1 | | 0% | 2 studies (2/-) | 67.3 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 0.60 [0.35, 1.03] | | < 1 | | 0% | 2 studies (2/-) | 96.8 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 1.28 [0.60, 2.75] | | < 1 | | 0% | 1 study (1/-) | 26.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Acute kidney injury TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 1.98 [0.18, 21.98] | | < 1 | | 0% | 2 studies (2/-) | 29.1 % | some concern | not evaluable | moderate | non important | - |
Alopecia TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.03 [0.00, 0.22] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.15 [0.03, 0.83] | | < 1 | | 0% | 2 studies (2/-) | 98.5 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 1.98 [0.18, 21.98] | | < 1 | | 0% | 2 studies (2/-) | 29.1 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.49 [0.04, 5.44] | | < 1 | | 0% | 2 studies (2/-) | 71.8 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.30 [0.05, 1.87] | | < 1 | | 0% | 2 studies (2/-) | 90.1 % | some concern | not evaluable | moderate | non important | - |
Dermatitis acneiform TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.97 [0.17, 5.60] | | < 1 | | 0% | 2 studies (2/-) | 51.5 % | some concern | not evaluable | moderate | non important | - |
Dyspepsia TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.83 [0.29, 2.39] | | < 1 | | 0% | 2 studies (2/-) | 63.6 % | some concern | not evaluable | moderate | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 1.98 [0.18, 21.98] | | < 1 | | 0% | 2 studies (2/-) | 29.1 % | some concern | not evaluable | moderate | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.98 [0.06, 15.84] | | < 1 | | 0% | 2 studies (2/-) | 50.4 % | some concern | not evaluable | moderate | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 2.30 [0.20, 26.34] | | < 1 | | 0% | 2 studies (2/-) | 25.3 % | some concern | not evaluable | moderate | non important | - |
Increased lipase level TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.16 [0.01, 3.32] | | < 1 | | 0% | 1 study (1/-) | 87.8 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.13 [0.02, 1.11] | | < 1 | | 0% | 2 studies (2/-) | 96.8 % | some concern | not evaluable | moderate | non important | - |
Nephritis TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.04 [0.01, 0.20] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
Pneumonia TRAE (grade 3-4) | 1.02 [0.06, 16.62] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 2.80 [0.41, 19.09] | | < 1 | | 0% | 2 studies (2/-) | 14.7 % | some concern | not evaluable | moderate | non important | - |
Pruritus TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 1.90 [0.33, 11.07] | | < 1 | | 0% | 2 studies (2/-) | 23.8 % | some concern | not evaluable | moderate | non important | - |
Stomatitis TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.07 [0.00, 1.18] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Alopecia AE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.16 [0.07, 0.34] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.95 [0.41, 2.23] | | < 1 | | 0% | 1 study (1/-) | 54.5 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.32 [0.03, 3.05] | | < 1 | | 0% | 1 study (1/-) | 83.9 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 1.91 [0.06, 57.12] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 1.44 [0.40, 5.14] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.38 [0.07, 1.96] | | < 1 | | 0% | 1 study (1/-) | 87.6 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.61 [0.58, 4.47] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 1.20 [0.47, 3.07] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.16 [0.02, 1.31] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.07 [0.02, 0.24] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 5.76 [0.29, 115.45] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 2.88 [0.30, 27.79] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.05 [0.01, 0.38] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.54 [0.16, 1.86] | | < 1 | | 0% | 1 study (1/-) | 83.5 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 2.88 [0.30, 27.79] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |